On the 6th of September the Phase lll trials of AZD 1222 were paused voluntarily across the globe to allow for a safety review by an independent committee and a team of international regulators.

The UK committee concluded its investigation and recommended to the MARA that the trails in the UK are safe to resume.

Under current rules of patient confidentiality further details about the exact nature that caused the pause cannot be disclosed, but all safety protocols will be adhered to and safety committees will be informed of progress on a continual basis.

There are a couple of important lessons to be drawn from the incident. While pauses in trial phases are quite normal the fact that in spite of the urgency and speed associated with the vaccine, safety guidelines are being strictly adhered to.

Additionally the fact that the pause was made public should go a long way in dismissing conspiracy theories that the speed of development will produce a flawed vaccine.